Hsp90 inhibitors and drug resistance in cancer: The potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs

MLA

Douglas M. Ruden, et al. “Hsp90 Inhibitors and Drug Resistance in Cancer: The Potential Benefits of Combination Therapies of Hsp90 Inhibitors and Other Anti-Cancer Drugs.” Biochemical Pharmacology, vol. 83, Apr. 2012, pp. 995–1004. EBSCOhost, https://doi.org/10.1016/j.bcp.2011.11.011.

APA

Douglas M. Ruden, Li Xiao, Xiangyi Lu, & Luan Wang. (2012). Hsp90 inhibitors and drug resistance in cancer: The potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochemical Pharmacology, 83, 995–1004. https://doi.org/10.1016/j.bcp.2011.11.011

Chicago

Douglas M. Ruden, Li Xiao, Xiangyi Lu, and Luan Wang. 2012. “Hsp90 Inhibitors and Drug Resistance in Cancer: The Potential Benefits of Combination Therapies of Hsp90 Inhibitors and Other Anti-Cancer Drugs.” Biochemical Pharmacology 83 (April): 995–1004. doi:10.1016/j.bcp.2011.11.011.